Bijal Shah, MD, MS, discusses the results of a phase 2 pilot study investigating CPX-351 in adults with high-risk relapsed/refractory acute lymphoblastic leukemia, as well as next steps for research in this patient population.
CPX-351 (Vyxeos), a liposomal formulation of cytarabine and daunorubicin provided encouraging activity and overall response rates in adults with high-risk relapsed/refractory acute lymphoblastic leukemia (ALL) or mixed phenotype leukemia, according to data from a phase 2 trial (NCT03575325).1
The small open-label, single-arm pilot study featured 6 patients with B-cell ALL, including 1 with B-myeloid disease. Additionally, 5 patients had T-cell ALL, including 4 with an early T-cell phenotype. Moreover, a TP53 mutation was noted in 5 patients. Of the 10 evaluable patients, 3 had a complete response (CR) or CR with incomplete count recovery (CRi), and further research with this agent is warranted, according to Bijal Shah, MD, MS.
We were happy with how CPX-351 performed in this pilot cohort, Shah said. This sets up a benchmark for expectations with single-agent CPX-351. It also tells us about who were going to be enrolling into relapsed and refractory trials as we go forward with the approvals of these novel agents in B-cell ALL.
In an interview with OncLive, Shah, associate member in the Department of Malignant Hematology at Moffitt Cancer Center, discussed the results of the phase 2 pilot study, as well as next steps in the patient population.
Shah: When we talk about how T cells kill, theres the assumption that its largely a perforin/granzyme mediated cell-killing event. What was shared was that there may be other mechanisms involved here, including the induction of apoptosis in lymphoblasts, and what the investigators saw on a [CRISPR/Cas9] screen was that when you lose some of the proteins that help mediate apoptosis, you lose your CAR T-cell killing efficiency. There are 2 pieces to that.
One is that it seems like those cells can grow more rapidly. More proliferative leukemias are harder to kill. The other part of the equation is the T cells are less effective in eliminating those cells, despite perforin and granzyme production, and, classically, what we think of as T-cell mediated killing. Some of that may relate to the fact that the T cells are becoming exhausted as they proceed down this path and keep trying to kill this blast population that doesnt want to accept defeat.
When we do genetic testing of leukemia, were not often looking at mutations or other changes along the apoptosis pathway. But it does suggest that we need to think more carefully, particularly in the more proliferative leukemias, to see whether there is an enrichment for those mutations that come with that enhanced resistance to CAR [T-cell therapy]. This fits into a whole category that were seeing as they relate to intrinsic CAR T-cell resistance.
We have talked about CD19 antigen downregulation, as well as CD58 and how that may affect CAR T-cell therapy and cancer interactions. Were starting to now get a flavor for all these things, touching specifically on intrinsic features in lymphoma. I hope were also going to start to better understand tumor microenvironment features.
Dr Ruella talked about his studies looking at the microbiome and how that may affect T-cell biology. We know that antigen-presenting cells, or along that same spectrum, myeloid dendritic suppressor cell populations, can affect both the expansion and the contraction of T cells over time. There are a lot of moving parts here [in figuring out how we can] improve the activity of CAR T-cell therapies and the durability of cell killing.
[Regarding] toxicity, it seems like that may be more reaction to the T-cell growth rather than the T cells directly driving this phenotype. Targeting some of these pieces of the tumor microenvironment also improves toxicity, which, interestingly, may also improve T-cell activity and the durability of that activity.
Its a rapidly evolving field, and its great to see. Hopefully well get to a point where we can talk about CAR T-cell therapy as a replacement for chemotherapy. Thats the ultimate goal.
Although Im excited about [CAR T-cell therapy as a replacement for chemotherapy], it is true that there are other things that are happening, including a trial that we did examining [CPX-351].
This is the liposomal formulation of daunorubicin and cytarabine. We want to get rid of chemotherapy, but as it turns out, not everyone is an immunotherapy candidate. Weve seen this in clinical practice. There are [patients] who are still on immunosuppressive therapy following an allogeneic stem cell transplant, and there are [patients] who dont have B-cell ALL. T-cell ALL remains an area that were struggling to target from an immunotherapeutic standpoint. We wanted to try to understand what we could accomplish [with this agent].
This was a pilot study with 11 patients. The observations were interesting, and 1 of the key observations was who we enrolled. We have novel trials for ALL, including with CAR T-cell immunotherapy. Six [patients] who came onto [the study] had B-cell ALL, including 1 B-myeloid overlap.
Of the remaining 5 patients with T-cell ALL, 4 had an early T-cell phenotype. That tells us where some of our gaps are. When we look to the biology, 5 of the 10 evaluable patients had a TP53 mutation. [Additionally], 2 had [Philadelphia chromosomelike] changes, speaking to the high-risk nature of the patients who were enrolled to the study. They had a median of 3 prior lines of therapy, with a range of 1 to 7. Seven had primary refractory disease. When we talk about prior therapies for the B-cell ALL cohort, that included blinatumomab [Blincyto; n = 5], inotuzumab ozogamicin [Besponsa; n = 2], and CAR T-cell therapy [n = 1]. [Moreover], 3 patients had prior [allogeneic stem cell transplant]. This was a very heavily pretreated population, with [a] high [prevalence of] TP53 mutations and high rates of early T-cell precursor and B-myeloid phenotypes. [These were] the groups that you would expect since we dont have great therapies for this group of patients.
We did see pancytopenia during induction as you would expect with cytarabine and daunorubicin. We did see febrile neutropenia in 9 [patients]. In terms of severe infections, it wasnt what I would have predicted, particularly having been involved in the studies of CPX-351 in acute myeloid leukemia. We had 1 patient who [died] from pneumonia. This was a patient who had B-cell ALL, and she failed to collect for CAR T-cell therapy [since] she had low lymphocyte counts. We had hoped to intubate her and support her through the process, but she and her family decided to move to comfort measures in lieu of intubation.
A second patient developed grade 3 sepsis, which resolved without any significant issues. All other infections in the remaining patients were grade 1 to 2. The only atypical thing that we saw [in terms of] severe, unexpected adverse [effects] was 1 gastrointestinal bleed. This was in a patient who had prior allogeneic transplant, and there was a concern that this may have reflected some component of graft-versus-host disease, [GVHD], although we couldnt confirm that. We had 3 grade 1 spontaneous subdural bleeds. [Those patients] all had low platelets, but we do see low platelets commonly in ALL without bleeding. This was a novel observation.
We had 1 patient develop veno-occlusive disease, but this is a patient who had prior inotuzumab [ozogamicin] and allogeneic transplant, so it was difficult to connect that with the CPX-351 therapy.
The infections that we saw were largely mild, meaning grade 1 to 2. Although we did see some unexpected cases of bleeding, [they] were incidentally appreciated in most cases and resolved.
The safety of this therapy was impressive in our patients with advanced ALL. The median time to neutrophil recovery was around 33 days. There were 2 patients who had refractory disease who didnt recover their platelets, but among the remaining patients, [recovery] was around 30 days. We did allow consolidation, so just as in the ALL trial, patients received an induction dose and then subsequent consolidation doses where the CPX-351 was given at a lower dose.
We saw 1 episode of foot cellulitis. This was a patient who had recurrent foot cellulitis prior to enrolling on the study. [We also observed] 1 episode of myocarditis. That ultimately was not attributed to the study drug.
In terms of responses, 3 patients achieved a CR or CRi including 2 in the early T-cell precursor group and 1 who had B-cell ALL.
We did see responses in the TP53 cohort, so that was very encouraging. [Of those 4 patients], 1 had a CR/CRi, and 1 showed a reduction of blasts but not enough to meet the criteria for CR. One went on to receive consolidation, and one was bridged to a donor leukocyte infusion.
It seemed like we were succeeding in terms of supporting these patients. The median time to next therapy was about 2.5 months, so 76 days. The median overall survival for the patients was 218 days, so it seemed to come with some clinical benefit.
With regard to what happened when patients progressed, after CPX-351, we only saw responses to any subsequent therapy in 2 patients. The other 8 patients were refractory to every subsequent therapy that was administered, ranging from chemotherapy to targeted therapy. This speaks to the nature of the patients that were enrolled.
Next steps are to figure out what we can do with CPX-351. That may be combining it with novel agents like venetoclax [Venclexta] or even asparaginase [crisantaspase, erwinase]. It may also mean continuing to treat more intensively since we really didnt see any significant toxicity in the consolidation phases.
Once patients moved to the lower intensity CPX-351, they were more likely to progress, if they didnt go on to transplant. We would probably want to think about continuing the induction dosing for at least 1 additional cycle to help deepen responses for some of these patients.
Originally posted here:
Pilot Study Shows Promising Results With CPX-351 in Relapsed/Refractory ALL - OncLive
- Unable to find a partner for stem cell therapy, Gamida accepts sale to investment firm to survive - Fierce Biotech - March 28th, 2024
- Putting Stem Cell-Based Therapies in Context - National Institutes of ... - January 31st, 2024
- Global Stem Cell Therapy Industry Outlook to 2028, Driven by Therapeutic Innovations and Clinical Advancements ... - Yahoo Finance - January 31st, 2024
- Stem Cell Transplant and CAR T-cell Therapy: The Patient and Care Partner Experience | BMT Infonet - BMT Infonet | - January 31st, 2024
- New study on promising stem cell-based therapy for Crohn's disease - Medical Xpress - January 31st, 2024
- The Trouble With Stem Cell Therapy - Consumer Reports - December 20th, 2023
- Stem Cell Therapy Boosts Quality of Life for People With Advanced Heart Failure - MedicineNet - December 20th, 2023
- The stem cell therapy project Blue4Therapy brought to a highly successful close - Marketscreener.com - April 7th, 2023
- Stem Cell Therapy for Spinal Cord Injury - PubMed - December 27th, 2022
- How much does stem cell therapy cost in 2022? - The Niche - December 18th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - December 18th, 2022
- Ethical issues in stem cell research and therapy - December 10th, 2022
- EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator Initiated Trial for ET-01, its Investigational Gene Editing... - November 6th, 2022
- Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood... - October 21st, 2022
- Global Cell Culture Protein Surface Coating Market to Grow at a CAGR of 13.82% During 2022-2031; Market to Expand on the Back of the Technological... - October 21st, 2022
- Stem Cell Therapy for Knees - thriveMD Denver & Vail, CO - October 13th, 2022
- Stem cell therapy and autism | Raising Children Network - October 13th, 2022
- Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patients with ... - The Bakersfield Californian - October 13th, 2022
- Global Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 - Yahoo Finance - October 13th, 2022
- 2023 to be highly lucrative for drug developers across therapeutic areas: Report - BSI bureau - October 13th, 2022
- Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and ... - October 4th, 2022
- Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the... - October 4th, 2022
- Innovative Imaging Techniques to Accelerate the Discovery of New... - Healthcare Tech Outlook - October 4th, 2022
- Celtic-mad dad left unable to talk after horror attack as family fundraise for stem cell therapy... - The Scottish Sun - September 25th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - Benzinga - September 16th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire - September 16th, 2022
- Radical lupus treatment uses CAR T-cell therapy developed for cancer - New Scientist - September 16th, 2022
- Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with... - September 16th, 2022
- T-Cell Redirection Therapy Shows Promise As Salvage Therapy in R/R Multiple Myeloma - Targeted Oncology - September 16th, 2022
- Orca Bio expands manufacturing capabilities to take cell therapies through to commercialization - BioPharma-Reporter.com - September 16th, 2022
- BioRestorative Therapies : BRTX Presentation September 2022 - Marketscreener.com - September 16th, 2022
- Advanced cellular therapy brings hope to KSA cancer patients - Omnia Health Insights - September 16th, 2022
- IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400 - BioSpace - September 16th, 2022
- The five hottest private biotech companies in India - Labiotech.eu - September 16th, 2022
- Be The Match and William G. Pomeroy Foundation Announce $500k Gift and Matching Campaign - PR Newswire - September 16th, 2022
- California man appears to be another person cured of HIV after a stem cell transplant - aidsmap - August 5th, 2022
- Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies - PR... - August 5th, 2022
- Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026 - Benzinga - August 5th, 2022
- The Role of Cell Banking Outsourcing Market Industry Growth, Competitors Analysis, New Technology, Trends and Forecast 2020 2030 - Digital Journal - August 5th, 2022
- World to Witness Surging Use of Neurostimulation & Neuromodulation Devices for Nerve Repair and Regeneration, Predicts Fact.MR - GlobeNewswire - August 5th, 2022
- Dr. Owhofasa Agbedia Honored With The 2022 ASH-CIBMTR-ASTCT Career Development Award - Business Wire - August 5th, 2022
- Novel Drug-Chemotherapy Combo After Stem Cell Transplant Associated With 'Favorable Survival Outcomes' in Group of Rare Blood Cancers - Curetoday.com - July 27th, 2022
- Broadening access to cancer fighting therapy led by UH researcher | University of Hawaii System News - University of Hawaii - July 27th, 2022
- Petition calling for 'life-changing' MS treatment funding handed to Parliament - Stuff - July 27th, 2022
- How effective is stem cell therapy for liver cirrhosis? - Times of India - July 27th, 2022
- Kite's CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) - Gilead Sciences - July 27th, 2022
- S'porean doctor, a sought-after top expert in cell therapy, appointed to WHO expert panel - The Straits Times - July 27th, 2022
- Top 10 Advances in Large B-Cell Lymphomas in the Past 10 Years - Targeted Oncology - July 27th, 2022
- Stem Cell Therapy Market Emerging Trends to Make Driving Growth on Key Players Status - Taiwan News - July 19th, 2022
- PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT - Dove Medical Press - July 11th, 2022
- Global Stem Cell Manufacturing Market Value Projected To Reach USD 21.71 Billion By 2029, Registering A CAGR Of 9.1% - Digital Journal - July 11th, 2022
- Diabetic foot treatment: Here's all you need to know about stem cell therapy - Hindustan Times - July 11th, 2022
- Every 5 minutes someone in India is diagnosed with blood cancer or a blood disorder: Patrick Paul, CEO, DKMS BMST Foundation India - The Financial... - July 11th, 2022
- Growing Prevalence & Recurrence Of Rheumatoid Arthritis Is Expected To Growth Of The Rheumatoid Arthritis Stem Cell Therapy Market Designer Women... - July 11th, 2022
- New sickle cell disease gene therapies depend on getting the right mouse - EurekAlert - July 11th, 2022
- Market Share, Supply, Analysis and Forecast of Human Insulin Drugs and Delivery Devices to 2026 Designer Women - Designer Women - July 3rd, 2022
- Gamida Cell Submits Biologics License Application for Omidubicel to the FDA - Pharmacy Times - June 22nd, 2022
- Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -... - June 22nd, 2022
- Stem Cell Therapy in Jacksonville at Pangenics Regenerative Center - June 13th, 2022
- Stem-Cell Based Therapy Shows Promise in Treating High-Risk Type 1 Diabetes - Newswise - June 13th, 2022
- What Is Myelofibrosis? Symptoms, Causes, Diagnosis, Treatment, and Prevention - Everyday Health - June 13th, 2022
- European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma - Targeted Oncology - June 13th, 2022
- Global Human Embryonic Stem Cell Market To Be Driven By The Rapid Technological Advancements In The Forecast Period Of 2022-2027 The Greater... - June 4th, 2022
- Pancreatic Cancer Therapy Experiment Saves Woman; Is It A Breakthrough? - Kaiser Health News - June 4th, 2022
- Dedication, Achievement and Grace in Cancer Care - Curetoday.com - June 4th, 2022
- Nerve Repair and Regeneration Market worth $11.6 billion by 2027 - Exclusive Report by MarketsandMarkets - Yahoo Finance - June 4th, 2022
- Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis - DocWire News - June 4th, 2022
- CPX-351 in Treatment of AML and Clinical Considerations - OncLive - June 4th, 2022
- High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study - AJMC.com Managed Markets Network - June 4th, 2022
- JASPER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - May 15th, 2022
- Cell Culture Market to Gain US$ 27.6 Bn by 2031, Burgeoning Demand for Biosimilars and Biologic Therapeutics Fueling Market Growth - BioSpace - May 15th, 2022
- Primary Cell Culture Market Mechanical Separation Segment Is Expected To Witness A Lucrative CAGR Of 11.7 - Benzinga - May 15th, 2022
- Vale man with MS needs 50,000 for treatment in Mexico - Evesham Journal - May 2nd, 2022
- Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO... - May 2nd, 2022
- Long-Term Axi-Cel Data 'May Be Suggestive of a Cure' in Patients With Large B-Cell Lymphoma - Curetoday.com - May 2nd, 2022
- Billy Connolly donates painting to Glasgow woman diagnosed with cancer five times - Glasgow Times - May 2nd, 2022
- The Progress Made in Stem Cell Therapy, Regenerative Medicine: Peter J. McAllister, MD, FAAN - Neurology Live - April 19th, 2022
- AACR: Resistance Mechanisms to CAR-T Cell Therapy ID'd in ALL - HealthDay News - April 19th, 2022
- 2022-04-18 | NDAQ:BRTX | Press Release | BioRestorative Therapies Inc - Stockhouse - April 19th, 2022
- First Patient With Lymphoma Receives Novel Cell Therapy in Large-Scale Trial - Curetoday.com - April 6th, 2022